Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” for the SQ-25012 injection issued by the State Drug Administration and agreed to carry out clinical trials with this product intended to treat thyroid eye disease.

Sq-25012 injection is a recombinant humanized IgG1 trispecific antibody. It is a class 1 innovative therapeutic biological product developed by the company. It is clinically intended to treat thyroid eye diseases. According to the requirements for Class 1 injections of innovative therapeutic biological products, the company has completed research on various aspects such as pharmacology and non-clinical pharmacology and toxicology of the SQ-25012 injection. The research results show that the SQ-25012 injection has good safety and clinical development value.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.